Abstract
The Ph 3 IMpower010 study (NCT02486718) met its primary endpoint, showing significant disease-free survival (DFS) benefit with atezo vs best supportive care (BSC) after adjuvant chemo in patients (pts) with completely resected stage II-IIIA NSCLC (HR 0.79 95% CI 0.64, 0.96), with pronounced benefit in PD-L1 TC≥1% stage II-IIIA pts (HR 0.66 95% CI 0.50, 0.88). We report data from the Asian population (pts recruited from Japan, mainland China, Taiwan, Korea and Hong Kong).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
